A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm

Study Identifier
TRU2011
CT.gov Identifier
NCT01814774
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Movement Disorders - Other
  • Eye Care - Other
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years * treatment with Xeomin® and BOTOX® for at least 1 year each
    Exclusion Criteria:
    * having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission * previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm

    Protocol Summary

    This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.

    Study Locations

    Location
    Status
    Location
    Bergen, Norway
    Status
    Not applicable
    Location
    Wakefield, United Kingdom
    Status
    Not applicable